Loading
A phase 3 trial of Oxaliplatin and Capecitabine in biliary tract cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure is a phase 3 interventional study registered as NCT07606599 by Sichuan Baili Pharmaceutical Co., Ltd., with 398 participants planned, started 2026-07-07 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1, Oxaliplatin, Calcium levofolinate, Fluorouracil, Irinotecan Hydrochloride Liposome and Irinotecan Hydrochloride.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SystImmune / Sichuan Biokin, Oxaliplatin, Capecitabine, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/